Cargando…

Quantifying the survival benefit of completing all the six cycles of radium-223 therapy in patients with castrate-resistant prostate cancer with predominant bone metastases

A retrospective analysis was performed of epidemiological data assessing the survival of patients who had received radium-223 for castrate-resistant metastatic prostate cancer treated at a regional tertiary referral center over a 5-year period. The patients' age, date of first treatment, and th...

Descripción completa

Detalles Bibliográficos
Autores principales: Buscombe, John, Gillett, Daniel, Bird, Nick, Powell, Anne, Heard, Sarah, Aloj, Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286012/
https://www.ncbi.nlm.nih.gov/pubmed/34321965
http://dx.doi.org/10.4103/wjnm.WJNM_74_20
_version_ 1783723655318994944
author Buscombe, John
Gillett, Daniel
Bird, Nick
Powell, Anne
Heard, Sarah
Aloj, Luigi
author_facet Buscombe, John
Gillett, Daniel
Bird, Nick
Powell, Anne
Heard, Sarah
Aloj, Luigi
author_sort Buscombe, John
collection PubMed
description A retrospective analysis was performed of epidemiological data assessing the survival of patients who had received radium-223 for castrate-resistant metastatic prostate cancer treated at a regional tertiary referral center over a 5-year period. The patients' age, date of first treatment, and the number of cycles of radium-223 given were obtained from the patients' electronic patient record (EPR). Data on the date of death were provided by national death registrations which update the EPR via a unique national health service number. A total of 187 patients (mean age on the date of first treatment: 73 years; range: 56–93) were treated from April 1, 2014, to June 30, 2019. The median overall survival of the 119 patients (71%) who had died by December 31, 2019, was 15 months. There was no significant age difference between those who had died and survivors (72 vs. 74 years). On a further analysis, it was found that the median overall survival of the 107 patients who had received all the six cycles of radium-223 was 31 months, significantly longer than the median overall survival of only 6 months for those eighty patients who had received less than the full course of six cycles of radium-223 (P = 0.001). Of those who received all the six cycles of treatment, 58 patients had died (58%) and the 1-year survival was 87%. This was compared to the group of patients receiving <6 cycles of radium-223 where 61 patients (76%) had died and the 1-year survival was 30%. Therefore, the hazard ratio of dying before 1 year if the patient did not receive all the six cycles of treatment was 2.9. Where the reason for stopping treatment was recorded on the EPR the most common cause for the cessation of treatment was because of the side effects caused by the treatment itself. Other causes were hospitalization with comorbidities, disease progression, or patient choice. Given the survival advantage of receiving the full course of all the six cycles of treatment, this should be administered if possible and the patients should be managed in such a way as to allow the complete treatment course to be given.
format Online
Article
Text
id pubmed-8286012
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-82860122021-07-27 Quantifying the survival benefit of completing all the six cycles of radium-223 therapy in patients with castrate-resistant prostate cancer with predominant bone metastases Buscombe, John Gillett, Daniel Bird, Nick Powell, Anne Heard, Sarah Aloj, Luigi World J Nucl Med Original Article A retrospective analysis was performed of epidemiological data assessing the survival of patients who had received radium-223 for castrate-resistant metastatic prostate cancer treated at a regional tertiary referral center over a 5-year period. The patients' age, date of first treatment, and the number of cycles of radium-223 given were obtained from the patients' electronic patient record (EPR). Data on the date of death were provided by national death registrations which update the EPR via a unique national health service number. A total of 187 patients (mean age on the date of first treatment: 73 years; range: 56–93) were treated from April 1, 2014, to June 30, 2019. The median overall survival of the 119 patients (71%) who had died by December 31, 2019, was 15 months. There was no significant age difference between those who had died and survivors (72 vs. 74 years). On a further analysis, it was found that the median overall survival of the 107 patients who had received all the six cycles of radium-223 was 31 months, significantly longer than the median overall survival of only 6 months for those eighty patients who had received less than the full course of six cycles of radium-223 (P = 0.001). Of those who received all the six cycles of treatment, 58 patients had died (58%) and the 1-year survival was 87%. This was compared to the group of patients receiving <6 cycles of radium-223 where 61 patients (76%) had died and the 1-year survival was 30%. Therefore, the hazard ratio of dying before 1 year if the patient did not receive all the six cycles of treatment was 2.9. Where the reason for stopping treatment was recorded on the EPR the most common cause for the cessation of treatment was because of the side effects caused by the treatment itself. Other causes were hospitalization with comorbidities, disease progression, or patient choice. Given the survival advantage of receiving the full course of all the six cycles of treatment, this should be administered if possible and the patients should be managed in such a way as to allow the complete treatment course to be given. Wolters Kluwer - Medknow 2020-10-23 /pmc/articles/PMC8286012/ /pubmed/34321965 http://dx.doi.org/10.4103/wjnm.WJNM_74_20 Text en Copyright: © 2020 World Journal of Nuclear Medicine https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Buscombe, John
Gillett, Daniel
Bird, Nick
Powell, Anne
Heard, Sarah
Aloj, Luigi
Quantifying the survival benefit of completing all the six cycles of radium-223 therapy in patients with castrate-resistant prostate cancer with predominant bone metastases
title Quantifying the survival benefit of completing all the six cycles of radium-223 therapy in patients with castrate-resistant prostate cancer with predominant bone metastases
title_full Quantifying the survival benefit of completing all the six cycles of radium-223 therapy in patients with castrate-resistant prostate cancer with predominant bone metastases
title_fullStr Quantifying the survival benefit of completing all the six cycles of radium-223 therapy in patients with castrate-resistant prostate cancer with predominant bone metastases
title_full_unstemmed Quantifying the survival benefit of completing all the six cycles of radium-223 therapy in patients with castrate-resistant prostate cancer with predominant bone metastases
title_short Quantifying the survival benefit of completing all the six cycles of radium-223 therapy in patients with castrate-resistant prostate cancer with predominant bone metastases
title_sort quantifying the survival benefit of completing all the six cycles of radium-223 therapy in patients with castrate-resistant prostate cancer with predominant bone metastases
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286012/
https://www.ncbi.nlm.nih.gov/pubmed/34321965
http://dx.doi.org/10.4103/wjnm.WJNM_74_20
work_keys_str_mv AT buscombejohn quantifyingthesurvivalbenefitofcompletingallthesixcyclesofradium223therapyinpatientswithcastrateresistantprostatecancerwithpredominantbonemetastases
AT gillettdaniel quantifyingthesurvivalbenefitofcompletingallthesixcyclesofradium223therapyinpatientswithcastrateresistantprostatecancerwithpredominantbonemetastases
AT birdnick quantifyingthesurvivalbenefitofcompletingallthesixcyclesofradium223therapyinpatientswithcastrateresistantprostatecancerwithpredominantbonemetastases
AT powellanne quantifyingthesurvivalbenefitofcompletingallthesixcyclesofradium223therapyinpatientswithcastrateresistantprostatecancerwithpredominantbonemetastases
AT heardsarah quantifyingthesurvivalbenefitofcompletingallthesixcyclesofradium223therapyinpatientswithcastrateresistantprostatecancerwithpredominantbonemetastases
AT alojluigi quantifyingthesurvivalbenefitofcompletingallthesixcyclesofradium223therapyinpatientswithcastrateresistantprostatecancerwithpredominantbonemetastases